SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
Related Experiment Videos
Robert M Bell1, Derek M Yellon1
1The Hatter Cardiovascular Institute, University College London, London WC1E 6HX, UK.
The Lancet. Diabetes & Endocrinology
|October 15, 2017
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The Fatty Acid Transporter CD36 Mediates Uptake, Biodistribution, and Cardioprotection by Small Extracellular Vesicles From HEK293 Cells.
Journal of extracellular vesicles·2026
Selective ROCK2 inhibition reduces microvascular obstruction but does not reduce myocardial infarction after ischaemia and reperfusion.
Journal of molecular and cellular cardiology plus·2026
The contribution of cardiomyocyte hypercontracture to the burden of acute myocardial infarction: an update.
Basic research in cardiology·2025
The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO.
The lancet. Diabetes & endocrinology·2026
Hashimoto's thyroiditis: two decades on.
The lancet. Diabetes & endocrinology·2026
Diabetes and the role of primary care: a global perspective.
The lancet. Diabetes & endocrinology·2026
Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.
The lancet. Diabetes & endocrinology·2026
G-quadruplex ligand-mediated CHK1 and ERα suppression in endocrine-sensitive and endocrine-resistant luminal breast cancer cells.
Cell cycle (Georgetown, Tex.)·2026
Obeticholic acid: discovery, clinical translation, and regulatory withdrawal.
European review for medical and pharmacological sciences·2026
An Act of DeFianCe: Targeting DKK1 in Metastatic Colorectal Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Cardiac toxicity and dysrhythmias in acute poisoning: a ten-year cohort study.
Clinical toxicology (Philadelphia, Pa.)·2026